VEGA

Alina Obermann-Smith Honored as CISO of the Year 2024 for Revolutionary Project in Information Security

Retrieved on: 
Friday, March 15, 2024
VEGA, Organization, Partnership, CISO, TEL

This accolade was bestowed upon Alina for her pioneering project in the "Change of Times in Information Security" category, which has set a new benchmark for excellence and innovation within the industry.

Key Points: 
  • This accolade was bestowed upon Alina for her pioneering project in the "Change of Times in Information Security" category, which has set a new benchmark for excellence and innovation within the industry.
  • This achievement reflects our collective passion and commitment to setting new standards for innovation in information security," Alina remarked.
  • As the CISO of the Year 2024, Alina is poised to continue leading the way in the ever-evolving information security landscape.
  • For more information about the CISO Alliance and the CISO Award, please visit the CISO Alliance Website .

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Retrieved on: 
Tuesday, February 27, 2024
VEGA, ALTAIR, Division, Recurrence, Doctor of Philosophy, MYGN, Cancer, Myriad Genetics, WGS, Neoplasm, Medicine, Genetic testing, Patient, MRD, Genetics, Head, Colorectal cancer, Research, DNA

Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.

Key Points: 
  • Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.
  • The goal of SCRUM-MONSTAR-SCREEN-3 is to generate high-quality, prospective, clinical evidence showing MRD testing can be broadly applied across cancer types and to patients with different disease severity or staging.
  • “First generation MRD tests have made remarkable progress monitoring disease recurrence and progression in cancer types with high tumor or variant burden.
  • “We’ve designed Precise MRD to be highly sensitive for application across all cancer types and look forward to this study demonstrating its utility in cancer care.”

NewSpace India and SAB Launch Services sign Launch Services Agreement to fly cubesat on PSLV mission

Retrieved on: 
Tuesday, January 30, 2024
VEGA, Partnership, Orbit, NewSpace India Limited, SSLV, PSLV, NSIL, SAB, ISRO, Management

BENEVENTO, Italy, Jan. 30, 2024 (GLOBE NEWSWIRE) -- NewSpace India Limited (NSIL), the commercial arm of ISRO providing Launch Services on-board ISRO’s launch vehicles, and SAB Launch Services (SAB-LS), specialized in Launch Services for small satellites, signed at the end of 2023 a Launch Service Agreement for deploying smallsat in orbit.

Key Points: 
  • BENEVENTO, Italy, Jan. 30, 2024 (GLOBE NEWSWIRE) -- NewSpace India Limited (NSIL), the commercial arm of ISRO providing Launch Services on-board ISRO’s launch vehicles, and SAB Launch Services (SAB-LS), specialized in Launch Services for small satellites, signed at the end of 2023 a Launch Service Agreement for deploying smallsat in orbit.
  • This agreement represents a significant milestone in providing advanced and seamless solutions for small satellites complementing with PSLV and SSLV missions, the launcher portfolio with focus on commercial customers.
  • Mr. Radkakrishnan D, Chairman and Managing Director of NSIL, expressed enthusiasm about the partnership, "Our strategic collaboration with SAB empowers us to better serve the global small satellite community, also in light of our new small launch vehicle SSLV."
  • SAB-LS’s CEO, Marco Mariani, added, "This partnership is a testament to the dedication we've poured into improving our services offer.

Environmental Focus Drives Adoption of Electric Airport Buses in the Airport Transportation Industry

Retrieved on: 
Friday, September 22, 2023
VEGA, Cobus Industries, Airport bus, BYD Company, Airport, Yutong, Electricity, Newcastle Airport, Carbon, USD, Isuzu, Toyota, Volvo, International airport, Volkswagen, Traction, Growth, Revenue, Transport, Airline, Floral industry

A significant driver of this transformation is the rapid replacement of old diesel-powered airport buses with new electric buses.

Key Points: 
  • A significant driver of this transformation is the rapid replacement of old diesel-powered airport buses with new electric buses.
  • Manufacturers are focusing on launching electric airport buses to contribute to carbon-free cities, fueling market growth over the forecast period.
  • The adoption of electric airport buses is gaining traction among both public and private airports, aligning with zero-emission objectives.
  • Airports are increasingly prioritizing the adoption of electric buses, known for their eco-friendliness and minimal environmental impact.

Promotions Announced At Cygnus: A Strategic Step Towards Growth

Retrieved on: 
Tuesday, August 15, 2023
Cygnus, VEGA, Heart, Duke University, University, Maryville University, Marketing, Temple University, Disability, University of Wisconsin–Madison, Organization, Student, Growth, Integration, Management, Sales, New York University

Promotions Announced At Cygnus Education: A Strategic Step Towards Growth

Key Points: 
  • Promotions Announced At Cygnus Education: A Strategic Step Towards Growth
    Angi is a dynamic and creative leader with 15 years of successful progressive experience specializing in recruitment, marketing, admissions, student success, outreach, and business development.
  • To assist her teams in achieving business goals, she defines clear objectives and provides the resources and coaching they need to be successful.
  • She has served her community by volunteering for organizations that serve underprivileged students and students with disabilities.
  • Together, we embark on a new chapter, unified by our shared commitment to excellence, innovation, and growth.

Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

Retrieved on: 
Friday, July 28, 2023
Science, Biotechnology, Research, Oncology, Health, Medical Devices, Genetics, Clinical Trials, VEGA, DNA, CRC, ALTAIR, American Society of Clinical Oncology, Rated R, ASCO, MRD, Patient, Risk, Trifluridine/tipiracil, Medicine, Neoplasm, Recurrence, III, Society, NTRA, Disease, Medical imaging, Medical device, Nature Medicine, Natera

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297).

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297).
  • ALTAIR is the circulating tumor DNA (ctDNA)-guided treatment escalation arm of the CIRCULATE-Japan adaptive trial platform evaluating the utility of the Signatera molecular residual disease (MRD) test in patients with stage II-IV resectable colorectal cancer (CRC).
  • CIRCULATE-Japan also includes the observational GALAXY study and the randomized phase III VEGA trial for ctDNA-guided treatment de-escalation.
  • “We are proud to partner with our collaborators from CIRCULATE-Japan to accelerate precision medicine and transform care for patients with resectable CRC.”

PlantX Provides Update on Financial Statements

Retrieved on: 
Wednesday, November 30, 2022
VEGA, Nutritionist, Annual Filing Season Program, Cosmetics, Nature, Clothing, Risk, Life, British Columbia Securities Commission, Education, National Policy, SEDAR, Performing Life, Inc, CSE, SEC filing, Security (finance), Audit

As the digital face of the plant-based community, PlantX's platform is the one-stop shop for everything plant-based.

Key Points: 
  • As the digital face of the plant-based community, PlantX's platform is the one-stop shop for everything plant-based.
  • With its fast-growing category verticals, the Company offers customers across North America more than 5,000 plant-based products.
  • All statements contained herein that are not clearly historical in nature may constitute forward-looking information.
  • The forward-looking information contained herein includes, without limitation, the anticipated filing of the Annual Filings and the Interim Filings.

CULT & RAIN Launches its Metaverse Shopping & E-Commerce Platform

Retrieved on: 
Tuesday, November 29, 2022
VEGA, Spotify, Record, Skin, NFT, GENESIS, CORE, RAIN, ATLAS, Multimedia, USD, UX, Empire Records, HEX, READY, Non-fungible token, Meta, Collection, Web browser, TITAN, CULT, VR, Fashion, Online shopping, Metaverse

NEW YORK, Nov. 29, 2022 /PRNewswire/ --On Wednesday, November 30th, 2022, CULT&RAIN will launch a radical Metaverse shopping experience inside CULTR WORLD and a new e-commerce platform at cultandrain.com.

Key Points: 
  • NEW YORK, Nov. 29, 2022 /PRNewswire/ --On Wednesday, November 30th, 2022, CULT&RAIN will launch a radical Metaverse shopping experience inside CULTR WORLD and a new e-commerce platform at cultandrain.com.
  • CULTR WORLD is a web browser & mobile-first based Metaverse experience, which is simple and easy to access.
  • For our seasoned collectors and curious Web3 users, the CULTR SHOP experience provides a radical yet intuitive shopping UX.
  • For those who prefer a more traditional shopping experience, CULT&RAIN is also launching a conventional e-commerce platform for users to purchase the CORE COLLECTION.

PlantX Provides Update on Financial Statements

Retrieved on: 
Tuesday, November 15, 2022
VEGA, Cosmetics, Annual Filing Season Program, CSE, SEDAR, Nutritionist, National Policy, Mission statement, Company, SEC filing, Time, Education, Phrase, British Columbia Securities Commission, Risk, Nature, Life, Clothing, Audit, BC

As the digital face of the plant-based community, PlantX's platform is the one-stop shop for everything plant-based.

Key Points: 
  • As the digital face of the plant-based community, PlantX's platform is the one-stop shop for everything plant-based.
  • With its fast-growing category verticals, the Company offers customers across North America more than 5,000 plant-based products.
  • All statements contained herein that are not clearly historical in nature may constitute forward-looking information.
  • The forward-looking information contained herein includes, without limitation, the anticipated filing of the Annual Filings and the Interim Filings.

PlantX Announces Cease Trade Order

Retrieved on: 
Wednesday, October 19, 2022
VEGA, National Policy, Time, Investment Industry Regulatory Organization of Canada, Sale, Risk, BCSC, Mission statement, Life, Education, Annual Filing Season Program, British Columbia Securities Commission, Company, Legislation, Clothing, CSE, Universal Market Integrity Rules, Nature, SEC filing, Canadian Securities Exchange, Nutritionist, Phrase, CTO, Disclosure, Cosmetics, SEDAR, Audit, Security (finance), BC

VANCOUVER, BC, Oct. 19, 2022 /PRNewswire/ - PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) ("PlantX" or the "Company") announced today that, the British Columbia Securities Commission (the "BCSC") has issued a general "failure to file" cease trade order pursuant to National Policy 11-207 Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictionsdated October 18, 2022 (the "CTO").

Key Points: 
  • VANCOUVER, BC, Oct. 19, 2022 /PRNewswire/ - PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) ("PlantX" or the "Company") announced today that, the British Columbia Securities Commission (the "BCSC") has issued a general "failure to file" cease trade order pursuant to National Policy 11-207 Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictionsdated October 18, 2022 (the "CTO").
  • The CTO, amongst other things, replaces the management cease trade order, which was issued by the BCSC on August 2, 2022 and extended until October 14, 2022, in respect to the Chief Executive Officer and the Chief Financial Officer of the Company, which prohibited those officers from trading in the Company's securities until after the Company cured its disclosure defaults.
  • The Company expects the Interim Filings to be filed concurrently with or shortly after the filing of the Annual Filings.
  • The forward-looking information contained herein includes, without limitation, the anticipated filing date of the Annual Filings and Interim Filings.